ICON plc - Clinical Research Organisation (CRO) for Drug Development

Financial Times Digital Health Summit Europe

As co-sponsors, ICON and Intel® will be jointly participating on a panel discussing ‘The digital reinvention of clinical trials’. 25% discount on the full registration price for ICON clients.

ICON and the Intel® Pharma Analytics Platform

ICON announces agreement with Intel® allowing Integration of the Intel® Pharma Analytics Platform for Clinical Trials to capture de-identified, objective, high-quality, rich sensory data via sensors and wearable devices.

FIRECREST

Site performance ignited: Digital solutions increase efficiency in clinical trials by driving site performance.

ICON Insights

15 June 2018

The Future of Automation and Digital Transformation in Late Phase Research

Late phase studies are ripe for digitalisation, although not always in the same ways as Phase II and III programs.

11 June 2018

NASH Clearing Clinical Trial Hurdles in Race to $35 billion Market

NASH ranks among the world’s great emerging health threats

07 June 2018

Controlling Logistics Costs Can Significantly Reduce Trial Lab Expenses

ICON has developed a lab logistics program to reduce costs

07 June 2018

Making the Move to Virtual Clinical Trials

Late phase research, once the exception, is becoming the rule. Some post marketing evidence needs can be met with virtual studies, DtP and cyber studies.

30 May 2018

Data-driven Site Selection Aids Accelerated Study Start-Up

There is an increasing demand from sponsors for technology and data-driven solutions to improve site selection, study start- up and patient recruitment.

30 May 2018

Smart Ways to Collect Real-World Data for Device Trials

An insulin injector is significantly safer and easier to use, and therefore leads to fewer complications and better clinical outcomes.

11 April 2018

Scientific Publications: Best Practices in Publication Planning

This is the first posting in a three-part series drawn from ICON’s webinar, “Evolving Best Practices for Working with Authors—Authorship and Beyond.”

11 April 2018

Regenerative Medicine Advanced Therapy Designation - Supporting Expedition in Drug Development

Find out about the FDA's pathway to assist industry in expediting drug development.

11 April 2018

mHealth Devices Allow for Better Treatments and Clinical Outcomes

Benefits include better, more personalised, treatment and improved clinical outcomes, with fewer clinic visits and greater independence for patients.

Services

Therapeutics

Innovation

Insights

News & Events

About ICON

Improving Pharma R&D Efficiency

Immuno-oncology

Harnessing Technology to Maximise RWE Value

Transforming Trials